scholarly journals Complete Response after Short-Term Sorafenib Treatment in a Patient with Lymph Node Metastasis of Hepatocellular Carcinoma

2012 ◽  
Vol 5 (2) ◽  
pp. 380-384 ◽  
Author(s):  
Hajime Mizukami ◽  
Tatehiro Kagawa ◽  
Yoshitaka Arase ◽  
Fumio Nakahara ◽  
Kota Tsuruya ◽  
...  
Kanzo ◽  
2008 ◽  
Vol 49 (5) ◽  
pp. 218-223 ◽  
Author(s):  
Kazuhisa Nakamura ◽  
Yoshihisa Sato ◽  
Kei Kawagoe ◽  
Shuhei Okuyama ◽  
Hiroyasu Matsuoka ◽  
...  

2016 ◽  
Vol 46 (13) ◽  
pp. 1402-1408 ◽  
Author(s):  
Norihito Nakano ◽  
Tomokazu Kawaoka ◽  
Hiroshi Aikata ◽  
Fumi Honda ◽  
Yuki Nakamura ◽  
...  

2020 ◽  
Vol 13 (3) ◽  
pp. 1490-1494
Author(s):  
Shuntaro Aoki ◽  
Masato Yasui ◽  
Hironao Tajirika ◽  
Hideyuki Terao ◽  
Makoto Funahashi ◽  
...  

An 85-year-old female was admitted to our hospital for left ureteral cancer and para-aortic lymph node metastasis. To control hematuria, a laparoscopic retroperitoneal nephroureterectomy was performed, and papillary urothelial carcinoma (pT3b) was found. To treat para-aortic lymph node metastasis, she received chemotherapy with gemcitabine and nedaplatin. After 2 cycles, a computed tomography scan revealed its disappearance; however, bilateral lung metastases appeared. The patient was administered second-line therapy with pembrolizumab every 3 weeks. After 3 courses, lung metastases disappeared and she achieved a complete response. After the fifth administration of pembrolizumab, she was readmitted with right upper limb pain and weakness in both lower extremities. She was diagnosed with pembrolizumab-induced grade 3 peripheral neuropathy with Guillain-Barré syndrome-like onset. High-dose monocorticotherapy was initiated for treatment. Three weeks later, the pain and weakness of the limbs improved. After discharge, the dose of prednisolone was tapered and there was no relapse of adverse events. Pembrolizumab was discontinued at the onset of neuropathy, but she maintained a complete response.


2004 ◽  
Vol 36 (1) ◽  
pp. 79 ◽  
Author(s):  
Sang Min Yoon ◽  
Jong Hoon Kim ◽  
Eun Kyung Choi ◽  
Seung Do Ahn ◽  
Sang-wook Lee ◽  
...  

2019 ◽  
Vol 39 (4) ◽  
Author(s):  
Xiping Zhang ◽  
Binbin Tang ◽  
Dehong Zou ◽  
Hongjian Yang ◽  
Enqi Qiao ◽  
...  

Abstract Objectives: The present study aimed to discuss the impacts of changes to pathological indicators of patients with breast cancer upon the incidence of postoperative lymphedema of the upper limb and prognosis. Methods: 2597 female patients with breast cancer who received surgical treatment in our hospital were enrolled in the present study to evaluate the incidence of these patients’ postoperative lymphedema of the upper limb. Results: For patients with breast cancer, the incidence of postoperative lymphedema of the upper limb was related to T stage of breast cancer, lymph node metastasis, the number of metastatic lymph nodes, pTNM stage, and pathological types of breast cancer (P<0.05). Lymph node metastasis was an independent risk factor of lymphedema of the upper limb; lymph node metastasis and Ki-67 expression level were independent factors that impacted pathologic complete response rate of neoadjuvant chemotherapies. Patients’ mortality was correlated to pathological and molecular subtypes, Ki-67 expression level, ER expression level, PR expression level, and pTNM stage (P<0.05), among which the pTNM stage, Ki-67 expression level, and PR expression level were independent factors that affected prognosis of patients with breast cancer. Conclusion: Patients with lymph node metastasis were more prone to lymphedema of the upper limb, while it was easier for those whose Ki-67 expression level was high and who were not subject to lymph node metastasis to get a pathological complete response after receiving neoadjuvant chemotherapies. The prognosis was poorer among patients whose progesterone receptors were negative and Ki-67 expression levels were high at the advanced pTNM stage.


Sign in / Sign up

Export Citation Format

Share Document